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Abstract
Dendritic cells (DCs) can initiate and direct adaptive immune responses. This ability is exploitable in DC vaccination
strategies, in which DCs are educated ex vivo to present tumor antigens and are administered into the patient with
the aim to induce a tumor-specific immune response. DC vaccination remains a promising approach with the potential
to further improve cancer immunotherapy with little or no evidence of treatment-limiting toxicity. However, evidence
for objective clinical antitumor activity of DC vaccination is currently limited, hampering the clinical implementation.
One possible explanation for this is that the most commonly used monocyte-derived DCs may not be the best source
for DC-based immunotherapy. The novel approach to use naturally circulating DCs may be an attractive alternative. In
contrast to monocyte-derived DCs, naturally circulating DCs are relatively scarce but do not require extensive culture
periods. Thereby, their functional capabilities are preserved, the reproducibility of clinical applications is increased, and
the cells are not dysfunctional before injection. In human blood, at least three DC subsets can be distinguished,
plasmacytoid DCs, CD141+ and CD1c+ myeloid/conventional DCs, each with distinct functional characteristics. In
completed clinical trials, either CD1c+ myeloid DCs or plasmacytoid DCs were administered and showed encouraging
immunological and clinical outcomes. Currently, also the combination of CD1c+ myeloid and plasmacytoid DCs as well
as the intratumoral use of CD1c+ myeloid DCs is under investigation in the clinic. Isolation and culture strategies for
CD141+ myeloid DCs are being developed. Here, we summarize and discuss recent clinical developments and future
prospects of natural DC-based immunotherapy.
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dendritic cells, Cross-presenting dendritic cells, Cancer, Immunotherapy, Vaccination
Background
In 1973 Cohn and Steinman discovered a new type of
immune cell, the dendritic cell (DC) [1], which plays an
important role in the induction of specific immunity. DCs
are sentinels of the immune system, as they are deployed
throughout the body and monitor their surroundings for
antigens and danger signals derived from pathogens or tis-
sue damage. They are the most potent antigen-presenting
cells, able to initiate and modulate specific immune
responses.
In their immature state, DCs mainly reside in lymphoid
and peripheral tissues where they recognize and capture
antigens. Upon receiving an activating stimulus in the
presence of inflammatory signals, DCs undergo matur-
ation and migrate to lymphoid organs. DC maturation is
associated with functional and morphological changes, an
essential process for T-cell activation. The immature
phenotype of DCs is mainly characterized by a low surface
expression of MHC I and II molecules and co-stimulatory
molecules and a high capacity for phagocytosis that medi-
ates sampling of antigens [2]. DCs activated by so-called
“danger signals” become highly motile, their endocytic
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and phagocytic receptors are down-modulated, and
chemokine receptors that foster migration to lymphoid or-
gans are upregulated. Furthermore, cell surface expression
of MHC molecules and adhesion/co-stimulatory mole-
cules, such as CD40, CD54, CD80, CD83, and CD86 is up-
regulated, and production of specific cytokines is induced
[3]. In the lymphoid organs, mature DCs present proc-
essed exogenous peptides to naive CD4+ T-cells via MHC
class II and endogenous peptides to CD8+ T-cells via
MHC class I. In addition, some DCs have a superior cap-
acity to cross-present exogenous antigens on MHC class I
to CD8+ T-cells [2], which is important for the induction
of cytotoxic T-cell responses against tumor cells. Effective
T-cell priming in the lymphoid tissues requires three sig-
nals between DCs and T-cells: antigen presentation via
the MHC-peptide complex (signal 1), stimulation via
co-stimulatory molecules from the DC to the T-cell (signal
2), and immune-stimulatory cytokines in the microenvir-
onment (signal 3) [3].
The ability of DCs to initiate and direct adaptive im-
mune responses is exploited for cancer immunotherapy,
especially in DC vaccination. With DC vaccination, ma-
ture DCs loaded with tumor antigens ex vivo are injected
into cancer patients to induce tumor-specific effector
T-cells that aim to recognize and eliminate cancer cells
and induce immunological memory to control tumor
growth [4]. In the majority of clinical DC vaccination trials
conducted so far, DCs differentiated ex vivo from mono-
cytes or CD34+ progenitors have been used, since natur-
ally circulating DCs (nDCs) are present in the blood but
only constitute about 1% of blood mononuclear cells.
However, through the development of efficient isolation
techniques, the use of nDCs has recently become feasible.
In this review, we summarize and discuss recent clinical
developments of DC-based immunotherapy with nDC
subsets, comprising completed and ongoing clinical trials.
Lessons from DC vaccination with moDCs
Prompted by excellent results against transplanted mouse
tumors with bone marrow-derived DC cultures, the first
DC vaccination trials were performed in the late nineties.
The effect of various DC vaccination parameters on im-
munological and clinical outcome of vaccination has been
studied in numerous small phase I/II clinical trials in can-
cer patients. Most of these studies have been performed
with monocyte-derived DCs (moDCs), due to their easy
differentiation protocol in vitro.
Maturation of moDCs
MoDCs are mostly HLA-DR+/MHC-II+ CD11c+ BDCA3−
and frequently express CD16, CD14 and DC-SIGN, due to
their monocytic origin [5]. Their functions and appear-
ance are very divers, likely due to the inflammatory con-
text they are differentiating in and the variety of cytokine
cocktails that are used for their activation ex vivo. From
the first clinical studies it became evident that proper
activation of the DCs is of major importance for DC
vaccination of cancer patients, otherwise antigen-specific
tolerance is induced rather than antitumor immunity [6–
8]. Besides inducing expression of molecules important
for T-cell activation, maturation of DCs leads to upregula-
tion of chemokine receptors which promotes the migra-
tion of injected DCs to the lymph nodes and is thus of
importance for vaccination efficacy [9].
In vivo, DC maturation is triggered by pathogens or tis-
sue injury. In vitro, this can be mimicked by incubation
with pathogen recognition receptor agonists or a cocktail of
proinflammatory cytokines. A cytokine cocktail consisting
of tumor necrosis factor (TNF)α, interleukin (IL)-1β, IL-6
and prostaglandin E2 (PGE2), or monocyte-conditioned
medium with TNFα and PGE2 are the most widely used
methods for moDC maturation [10, 11]. Whether this is
the best cocktail to induce maturation remains controver-
sial since PGE2 may confer immunosuppressive effects [12,
13]. To further induce DC activation, mimicking viral infec-
tion, type I interferons have been added to the cocktail [14].
More recently, the use of Toll-like receptor (TLR) ligands
[15, 16] or electroporation with mRNA-encoding proteins
that induce DC maturation [17] has been explored. The lat-
ter methods yield DCs that produce higher levels of IL-12,
which favors the differentiation of T helper 1 (Th1) cells
and promotes activation of potent CD8+ effector T-cells.
Antigen loading and administration of moDCs
To induce a tumor-specific immune response in cancer
patients, DCs should be loaded with relevant tumor anti-
gens. The most widely used techniques for antigen loading
of DCs vaccines are pulsing DCs with MHC-binding pep-
tides of tumor-associated antigens (TAA), corresponding
long peptides or proteins, TAA-encoding mRNA, or
tumor lysate. All antigen-loading techniques have their ad-
vantages and disadvantages; none has proven to be super-
ior to the others thus far, however, loading with both
MHC class I and class II epitopes seems beneficial for the
quality of the induced immune response [18].
For DC vaccination, it is crucial that DCs migrate to
the T-cell areas of the lymph nodes after administration.
In murine models it was shown that intravenously
injected DCs mostly accumulate in highly vascularized
organs like spleen, lungs, kidneys and liver, rather than
lymph nodes and fail to induce skin-homing T-cells [19,
20]. Migration studies with labeled DCs demonstrated
that after intradermal injection, only 2–4% of the
injected cells migrate to draining lymph nodes, whereas
most of the injected cells die at the dermal injection site
and were cleared by macrophages [21–23]. After intra-
nodal injection, injected cells accumulate in the injected
node and subsequent draining lymph nodes [23, 24]. By
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leaving the DCs directly at the site of interaction with
T-cells, this route of administration obviates the need
for DCs to migrate. However, cells need to be injected
under ultrasound guidance.
Comparison of induced immune responses after DC
vaccination via different routes of administration showed
variable results [23, 25, 26]. Intradermal injection seems
to yield superior T-cell responses in terms of tumor
recognition and cytokine production [23], which might
in part be explained by the fact that, after intradermal
migration, only the most mature and most potent DCs
reach the lymph nodes, in contrast to intranodal injec-
tion, where also nonviable and less mature DCs are
directly delivered into the lymph nodes.
moDCs in clinical trials: the outcome
Thus far, numerous phase I/II clinical trials with moDC
vaccines have been performed in cancer patients.
Side-effects were minimal and included grade 1–2 flu-like
symptoms, fever and local injection site reactions. Grade
3–4 toxicity is very uncommon after DC vaccination but
can occur with more potent moDC formulations [15, 27–
29]. Thus, DC vaccination can be concluded to be safe
when used as monotherapy.
Although safe and able to induce anticancer immunity,
so far objective clinical responses have only been achieved
in a minority of patients after moDC vaccination, usually
around 5–15% of metastatic cancer patients. However,
despite the lack of clear benefit in objective clinical re-
sponses, a trend to survival benefit was reported in most
studies [28]. This is often seen with immunotherapy, as it
takes time until the full potential of the anti-tumor re-
sponse is reached and sometimes delayed objective clinical
responses occur, or only stable disease is achieved that
nevertheless can be highly durable. This dissociation be-
tween objective response and overall survival (OS) is ham-
pering the clinical implementation of DC vaccination as
larger randomized clinical trials would be required when
survival rather than tumor response is used as a primary
endpoint. Furthermore, most trials were conducted with
widespread metastatic patients in which tumor-induced
immune suppression is probably too strong to overcome
with DC vaccination alone. Still, numerous small trials im-
proved the quality of the DC vaccines over the years and
moDC vaccination still holds promise for clinical applica-
tion. Combination of DCs with other forms of anticancer
treatment might be a solution to overcome tumor-induced
immune suppression. For example, the combination of
moDCs with anti-CTLA4 blockade in advanced melanoma
patients showed an encouraging response rate of 38%, with
all complete responders (n = 7) still free from progression
and off-therapy more than 5 years after the initiation of
DC therapy [30]. Another option to obtain more robust
antitumor responses, might be adjuvant DC vaccination,
when only minimal tumor load in present [31, 32]. Data
from phase III clinical trials are needed to substantiate the
results of the successful smaller trials. Recently, OS data of
a randomized phase III clinical trial in glioblastoma
patients treated with a moDC vaccine in combination with
chemotherapy and radiotherapy were published [33]. The
median OS seems promising compared to literature, but
due to the cross-over trial design groups within the trial
cannot be properly compared and progression-free
survival (PFS) data is awaited.
Naturally circulating dendritic cells
MoDCs may not be the best DC source for immunother-
apy, since they have been described to have decreased mi-
gratory capacities towards the site of T-cell interaction by
exhaustion of the cells [34], probably due to the artificial
differentiation by cytokines and extensive ex vivo culture
periods. nDCs may be a potent alternative for moDCs, as
the brief ex vivo exposure of nDCs might preserve the
functional capabilities of the cells and prevent exhaustion.
Although direct comparison of nDCs and moDCs in
clinical trials have not been performed (yet) to validate the
in vitro data. In addition, The Cancer Genome Atlas
reveals that specific nDC subsets, rather than moDCs, are
associated with improved survival in diverse cancer types
[35–37]. Although the isolation of monocytes from the
blood has a much higher yield, direct isolation of nDCs is
now feasible and facilitates robust standardization for use
in multicenter trials and, eventually, standard care.
nDCs comprise a heterogeneous population of cells.
Functional, transcriptomic and proteomic reports identi-
fied the major circulating DC subsets, which are distin-
guished by distinct surface markers [38–40]. Human DCs
can be subdivided in two main subsets (Fig. 1); plasmacy-
toid DCs (pDCs) and myeloid/conventional DCs (mDCs).
These subsets differ in function, localization, and pheno-
type [41]. pDCs have a plasma cell-like shape and are
specialized in viral antigen recognition, they largely lack
expression of extracellular TLRs and are the main
producers of type I interferons (IFNs) [42, 43]. They are
mainly localized in T-cell areas of lymph nodes and
express BDCA2 and BDCA4 [41, 44]. pDCs appear to be
predominantly tolerogenic in the context of cancer and
correlate with poor prognosis [44]. However, when prop-
erly activated, they have the ability of cross-presentation
and may therefore be potent inducers of antitumor re-
sponses [45–47]. Activation of pDCs induces upregulation
of MHC molecules and costimulatory molecules, allowing
efficient priming of CD4+ and CD8+ T-cells. The secretion
of large amounts of type I IFNs can induce Th1
polarization as well as activation of innate immune cells,
such as macrophages and natural killer cells [45, 48–50].
Type I IFNs produced by pDCs are also beneficial for anti-
gen cross-presentation by mDCs [51]. mDCs are mainly
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localized in the marginal zone of lymph nodes and express
MHC II and CD11c [48, 52, 53]. They express extracellu-
lar TLRs (TLR1, TLR2, TLR4–6) and endosomal TLRs
(TLR3 and TLR8), which are responsible for the ability of
mDCs to secrete the Th1 skewing cytokine IL-12 upon ac-
tivation [43]. The mDC population can be further subdi-
vided into two classes based on surface expression into
CD1c(BDCA1)+ DCs (cDC2s) and CD141(BDCA3)+ DCs
(cDC1s), with the CD1c+ mDCs being the most potent
T-cell stimulators of these subpopulations [43, 54, 55].
CD1c+ mDCs also consist of two subsets, both popula-
tions stimulate T-cell proliferation but differ in their po-
tential for cytokine secretion [56]. CD1c+ mDCs seem
specialized in immunity against bacteria and fungi,
whereas CD141+ mDCs are specialized in detection and
uptake of necrotic cell debris of virally infected cells or
tumor cells and cross-presentation of derived antigens to
CD8+ T-cells [57–59]. Especially a subset of
BDCA3+XCR1+CLEC9A+ cells seems to be a superior
cross-priming DC subset in humans [57–61]. They can
migrate from peripheral organs to lymph nodes and effi-
ciently cross-present cell-associated antigens to induce
CD8+ T-cells [39, 40, 60, 62, 63]. Most recently, myeloid
DC have also found to be of pivotal importance in “re-
licensing” the antitumor activity of cytotoxic T-cells within
the tumor microenvironment [35, 37]. Furthermore, a
subset of CD16+ ‘non-classical’ monocytes with DC-like
characteristics is found in human blood [64].
In animal models, it was shown that mature
antigen-loaded pDCs or mDCs can prime tumor-specific
T-cell responses that result in tumor eradication [65–67]. In
a murine glioma model, vaccination with mDCs was super-
ior to pDCs in survival benefit [67]. Recent studies suggest
that pDCs and mDCs cooperate and act synergistically. In
mice, pDCs were shown to induce tumor-specific CD8+
T-cell responses and enhance the ability of mDCs to present
tumor antigens to T-cells [68, 69]. In human, mDCs and
pDCs were shown to activate each other after specific
stimulation of one of the subsets with TLR ligands in vitro
[53]. Combining the two subsets in one vaccine might thus
exploit their functions simultaneously and increase their im-
munotherapeutic potential [70].
Isolation of nDCs for clinical use
Production of DC vaccines is a labor-intensive process
comprising numerous open handling steps such as dens-
ity gradient cell processing, cell washing steps, cell label-
ing/separation, cell culture, final product formulation
and cryopreservation. The complexity of the process
makes it prone to failure and requires experienced
personnel and complex protocol development under
GMP guidelines. Therefore, manufacturing of clinical
Fig. 1 Dendritic cell subsets. Dendritic cells can be differentiated from monocytes (moDC), which are often used in clinical trials because of their
high yield. The naturally circulating dendritic cells can now also be enriched by immunomagnetic isolation. The naturally circulating dendritic
cells can further be divided in myeloid (CD141+ and CD1c+ mDC) and plasmacytoid dendritic cells (pDC). The subsets differ in function,
localization, phenotype and cytokine production
Bol et al. Journal for ImmunoTherapy of Cancer           (2019) 7:109 Page 4 of 13
grade DC vaccines can be performed only in highly special-
ized institutions and existing manufacturing processes are
hardly transferable, which in turn limits patient’s access to
this kind of therapy. To overcome these limitations, there
is a growing effort in the field to develop standardized, ro-
bust and reproducible protocols for production of DC vac-
cines. In this regard, automation of such processes is a
major step forward as it limits operator-dependent vari-
ance and thereby reduces deviations not only between indi-
vidual production runs but also between productions that
are performed at different clinical centers. Miltenyi’s Clini-
MACS Prodigy® platform consists of an integrated device,
clinical grade buffers and reagents and a single-use tubing
set that allows for temperature and atmosphere-controlled
cell culture. It has been designed to automatically perform
all cell handling steps in a closed system with minimal user
interaction for highest reproducibility [71]. In addition, the
closed system reduces the need for complex class A
clean-room resources as it can be operated in a class C
GMP-environment. The production of nDC vaccines con-
sists of positive selection to enrich pDCs and/or mDCs
using magnetic antibody-coupled beads, optionally pre-
ceded by depletion of monocytes and B cells (Fig. 2). Cur-
rently, two additional processes are under development
aiming for the isolation of cross-presenting CD141+ mDC
and panDC (pDC+CD1c+ mDC +CD141+ mDC).
Addition of CD141+ mDCs may further improve nDC vac-
cines, since this mDC subtype is highly efficient in antigen
cross-presentation and able to secrete IFNλ and IL-12
upon activation [57–59, 72].
nDCs in clinical trials: the vaccines
Currently, 9 clinical trials with autologous nDC vaccination
are performed in cancer patients, of which three are com-
pleted [73–75], one was terminated (ACTRN1260700
0450415), and 5 are ongoing (NCT02574377, NCT02
692976, NCT02993315) of which 2 are still recruiting pa-
tients (NCT03707808, NCT03747744). The trials included
patients with either melanoma, prostate cancer or any solid
tumor. Three trials focus solely on CD1c+ mDC vaccination
and one trial solely on pDC vaccination, whereas in the
remaining trials that are being performed the combin-
ation of both nDC cell types is studied or CD1c+ mDC
vaccination is combined with other immunotherapeu-
tics (Table 1). All trials performed isolation of DCs
using the immunomagnetic CliniMACS® isolation sys-
tem. Another method to obtain DCs from an apheresis
product is the enrichment of DCs by density centrifu-
gation. This method was mainly performed before the
emergence of magnetic separation. Magnetic separation
is a faster, less labor-intensive method and results in a
purer population of cells with a sufficient yield com-
pared to density centrifugation. As density centrifuga-
tion does not result in pure populations, studies
performing density gradient isolation were not included
in this review. Among these are studies using the clinic-
ally approved sipuleucel-T for metastatic castration-re-
sistant prostate cancer [76], which only contains a
small fraction of CD54+ DCs, i.e. stimulated DCs,
among T-cells, natural killer cells, monocytes, and
B-cells. In essence, the vaccination product is the result
of peripheral blood mononuclear cells (PBMCs)
obtained from apheresis activated by a fusion protein
between prostate acid phosphatase and granulocyte-
macrophage colony-stimulating factor (GM-CSF) [77].
The contribution of the diverse cell types to the activity
of the intravenously administered vaccination product
remains unclear.
mDC vaccines
The first clinical trial with mDCs, in 2007, was conducted
in hormone-refractory metastatic prostate cancer patients
(mDC-PROS1). Isolation of mDCs was performed by
positive selection for CMRF-56, an early DC activation/
differentiation antigen expressed by mDCs after in vitro
culture for 6 h [78, 79]. This single-step isolation proced-
ure showed higher yields as well as less variable purity
compared to the isolation by density gradients performed
in the clinical setting until then, but the product still con-
tained about 30% CD14+ and CD19+ cells [80]. Therefore,
this study was terminated and as the study results are not
published, no conclusions can be drawn concerning the
isolation and culture method.
In subsequent trials, the CD1c+ mDCs were selected
by depletion of B cells (CD19+) followed by positive se-
lection of CD1c+ cells. In the trial with metastatic mel-
anoma patients (mDC-MEL1), initiated in 2010, this
procedure resulted in an average purity of 93% and a
yield between 27 × 106 and 96 × 106. The isolated cells
were stimulated by GM-CSF, resulting in semi-mature
mDCs that are HLA-ABC/DQ/DR+ CD86+ and showed
variable CD83 and CD80 expression [74]. A trial con-
ducted with mDCs in metastatic prostate cancer patients
(mDC-PROS2) used the same selection technique and
obtained a similar purity (median 82%) and yield
(28-101 × 106). However, no stimulation was added in
this trial and phenotyping established that all CD1c+
cells within the vaccines had a semi-mature phenotype
(CD86+ CD40− CD80− CD83−) [75].
In 4 trials, to obtain CD1c+ mDCs, cells expressing the
monocytic marker CD14 were also depleted in addition to
CD19+ cells, since CD1c+ CD14+ cells were shown to sup-
press CD4+ T-cells and may severely hamper DC vaccine
efficacy [81]. In two trials with completed patient accrual,
stage III melanoma patients (combiDC-MEL1) or meta-
static prostate cancer patients (combiDC-PROS1) were ei-
ther vaccinated with mDCs, pDCs or the combination of
both. In the two ongoing trials, the mDCs are neither fully
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Fig. 2 Production protocols for naturally circulating dendritic cells. Schematic overview of the (a) CD1c+ myeloid dendritic cell (mDC) and (b)
plasmacytoid dendritic cell (pDC) production protocols and vaccination strategy of the various clinical trials
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matured nor loaded with antigen ex vivo, but injected
intratumorally in combination with Talimogene Laherpar-
epvec (T-VEC; mDC-MEL-TV), an oncolytic virus
approved for non-visceral melanoma metastasis [82], or
the immune checkpoint inhibitors anti-CTLA4 and anti-
PDL1 intratumorally and anti-PD1 intravenously (mDC-
SOLID-ICI). It is hypothesized that the semi-mature mDC
capture tumor antigens and mature in vivo after intratu-
moral exposure to the co-injected T-VEC virus or im-
mune checkpoint inhibitors, which have the potential to
elicit antigen-dependent cellular cytotoxicity and
complement-dependent cytotoxicity, thereby creating an
inflamed tumor microenvironment.
To stimulate the DCs in the combination trials, DCs
are activated with protamine/mRNA which can induce
maturation of both pDCs and CD1c+ mDCs [47]. Al-
though the two DC subsets do not express an overlap-
ping repertoire of TLRs, single-stranded RNA is a
suitable maturation stimulus as it is a ligand for TLR7
on pDCs and TLR8 on mDCs, inducing IFNα and IL-12
production, respectively. Furthermore, stimulation with
protamine/mRNA was shown to result in an increase in
the expression of MHC class I and CD86, and a variable
expression of CD80 on both mDCs and pDCs. Conse-
quently, the stimulated DCs were able to induce T-cell
proliferation and activation [47]. This characteristic of
protamine/mRNA to activate both CD1c+ mDCs and
pDCs provides more flexibility in combining the two
subsets in one vaccine. Preliminary data from these two
trials shows a similar phenotype as in the preclinical
study (unpublished data).
pDC vaccines
The pDCs, used in the combination trials and a trial with a
single pDC vaccine in melanoma patients (pDC-MEL1), are
isolated by BDCA4 bead-coupled antibodies, without any
prior depletion step. Compared to mDCs, pDCs have a
lower average purity of 75% and a yield between 13 × 106
and 33 × 106 cells [73]. Activation of the autologous pDCs
is either performed with Frühsommer-meningoencephalitis
(FSME) vaccine (pDC-MEL1) or protamine/mRNA (com-
bination trials). In contrast to mDCs, GM-CSF is not suit-
able as stimulus for pDCs, as it does not efficiently activate
pDCs to produce type I IFNs [74]. In contrast, FSME is a
suitable maturation stimulus for pDCs as it triggers TLR7,
leading to cytokine production and maturation [83].
Although outside the scope of this review, there is one
trial with a pDC vaccine in melanoma patients
(NCT01863108) using pDCs from an allogeneic cell line.
This cell line is derived from a malignant leukemic pDC
Table 1 Clinical trials with natural DC vaccination
aStage IV melanoma patients or irresectable stage III melanoma patients
bAnticipated capture of tumor antigens and maturation in vivo
cmDC vaccination in combination with T-VEC intratumorally or anti-CTLA4 and anti-PDL1 intratumorally and anti-PD1 intravenously
dAll mDCs obtained from the leukapheresis are injected
Abbreviations: FSME, Frühsommer-meningoencephalitis; GM-CSF, granulocyte-macrophage colony-stimulating factor; mDC, myeloid dendritic cell; pDC,
plasmacytoid dendritic cell; T-VEC, Talimogene laherparepvec. (source: clinicaltrials.gov and anzctr.org.au)
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and cells are irradiated prior to administration to prevent
further proliferation of pDCs in the patient [84]. The
advantage of an allogeneic cell line lies in the abolishment
of the limited cell yield and obviates the need for a leuka-
pheresis. Although vaccination with allogeneic DCs will in-
duce an allogeneic immune response, these responses
may even be beneficial for the antitumor response [85].
Preclinical studies showed that using allogeneic DCs
was safe and effective, however, the allogeneic DCs and
the patient must share a HLA antigen, in this case
HLA-A*02:01, to enable antigen presentation. Further-
more, there is a chance to develop immune reactions
against the DCs itself. In the case of repetitive vaccin-
ation this would lead to unwanted killing of the allo-
geneic DCs by the immune system.
Administration and antigen loading
In all but two trials a cycle of three vaccinations with a 2
to 4-week interval was administered. In the 4 trials per-
formed in Nijmegen, maximally two maintenance cycles
were given in the absence of progressive disease. In the
phase I trials combining mDCs with T-VEC or immune
checkpoint inhibition intratumorally, currently only a
single vaccination is given. Concerning the administra-
tion of the vaccine, the trials differ in the number of
cells that are administered, the administration schedule,
and the route of administration (Table 1). In all trials
using antigen loading, peptide pulsing was performed.
As electroporation procedures comes with moderate cell
toxicity, this is a serious drawback for the scarce nDCs.
The tumor antigens used differ between the trials,
mainly due to the different tumor types expressing dif-
ferent antigens. The number of cells mainly depend on
the yield of nDC isolation and ranges from 1 × 106 to
1 × 107 cells per vaccination. There is little evidence
about the most effective cell number per vaccination,
even for moDCs. In most trials intranodal injection was
performed, again due to the scarcity of the cells.
nDCs in clinical trials: the outcome
Monitoring immune responses
In all phase I/II trials, the primary and secondary end-
points were safety and immunological outcome. For
immunomonitoring purposes, DCs were loaded with a
control antigen in all trials performing antigen loading.
Both trials with CD1c+ mDCs (mDC-MEL1,
mDC-PROS2) used keyhole limpet hemocyanin (KLH)
as a control antigen and as a source for T helper epi-
topes. In the mDC-PROS2 trial, KLH-specific antibodies
could be detected by ELISA in the peripheral blood after
vaccination in 4 of 12 patients, of which one patient
already had KLH-specific antibodies prior to vaccination
[75]. In the mDC-MEL1 trial, KLH-specific antibodies
could be found in a similar percentage of patients (4 of
13 patients), with detectable KLH-specific antibodies
prior to vaccination in 2 patients but with increased
levels after vaccination. Also, T-cell proliferation upon
stimulation with KLH was shown in 11 of 13 patients
after the first round of vaccinations [74]. However, previ-
ously no correlation with survival and a strong
KLH-specific T-cell response could be found in a cohort
of 91 patients [86].
As pDCs do not have the capacity to take up soluble
KLH [87], KLH cannot be used for immunomonitoring
in patients vaccinated with pDCs. In the pDC-MEL1
trial, the FSME vaccine was used as a maturation stimu-
lus and served as a control antigen. In this study, periph-
eral blood showed T-cell proliferation upon stimulation
with FMSE in 10 of 14 patients tested, while
FMSE-specific antibodies were present in 12 of 15 pa-
tients [73]. The data on immune responses against the
control antigens indicate that nDC vaccination can ef-
fectively induce de novo immune responses in cancer
patients. As different control antigens were used, no dir-
ect comparison of the efficacy of the induction of the
novo immune responses between mDCs and pDCs can
be made.
All published trials also analyzed the presence of tumor
antigen-specific T-cells, either by FACS or ELIspot assays.
In the mDC-MEL1 trial, tumor antigen-specific T-cells
were detected in PBMCs of 4 of 12 patients [74]. In the
mDC-PROS2 trial no tumor antigen-specific T-cells could
be detected [88]. In the pDC-MEL1 trial, tetramer stain-
ings were negative, however, after in vitro restimulation
with antigenic peptides, an increase in tumor
antigen-specific T-cells after vaccination could be detected
in 7 of 15 patients [73]. This in vitro restimulation was
not performed in the other trials.
Furthermore, delayed-type hypersensitivity (DTH) skin
tests were performed in all 3 trials after (each round of) 3
vaccinations. In the mDC-PROS2 trial, DTH skin test
were conducted with prostate-specific peptides. No skin
reactions, pain/itching or erythema was observed to KLH
or prostate-specific peptide. However, skin reactions were
present against a control peptide (FMP) in 4 patients [75].
Unfortunately, no skin biopsies were taken for further
analyses, although swelling/erythema of a DTH skin test
does not correlate with the presence of tumor antigen-
specific T-cells [89] but the presence of tumor-specific
T-cells correlates with clinical outcome [86, 89]. There-
fore, in both trials performed in Nijmegen biopsies were
taken irrespective of induration of the DTH injection sites.
Tumor-specific CD8+ T-cells were detected with tetramer
stainings in 4 of 13 patients (mDC-MEL1) and 2 of 15 pa-
tients tested (pDC-MEL1) [73, 74]. Despite the small
number of patients in the mDC-MEL1 trial, the correl-
ation between the presence of tumor-specific T-cells and
survival could be observed [74].
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Toxicity and survival
Toxicity data for nDC vaccination thus far is limited, but
the toxicity seems to be similar or even more favorable
than with moDC (Table 2). To date, little can be con-
cluded on the clinical efficacy of nDC vaccination. In
both trials with metastatic melanoma patients, PFS was
short in most patients. However, in the trial with CD1c+
mDCs, PFS was longer in patients with tumor-specific
T-cells compared to patients without tumor-specific
T-cells. Furthermore, despite the short PFS in most pa-
tients, OS seems to be relatively long. The median OS
was 13 (mDC-MEL1) and 22 months (pDC-MEL1) [73,
74]. However, OS might be biased by subsequent treat-
ments. In the mDC-PROS2 trial, the asymptomatic
hormone-refractory metastatic prostate cancer patients
showed a median OS of 18 months, including one pa-
tient alive over 5 years after enrollment [75]. Of the
more recent trials, highly preliminary data of the intratu-
moral mDC vaccination in combination with immune
checkpoint inhibitors (mDC-SOLID-ICI) showed a dur-
able partial response (> 8 months) in a melanoma patient
who previously progressed on immune checkpoint in-
hibition [90]. More robust survival data should be ob-
tained from the first phase III trial with nDCs
(combiDC-MEL2). This trial started in 2016 and studies
vaccination with the combination of pDCs and CD1c+
mDCs compared to placebo in the adjuvant setting in
stage III melanoma patients. Due to the recent approval
of anti-PD1 antibodies and combined BRAF/MEK inhib-
ition as adjuvant treatment, the inclusion had to be
stopped before completing planned accrual. However,
the circa 150 enrolled patients will provide valuable re-
sults in the near future.
Future perspectives: CD141+ mDCs, neoantigens and in
vivo targeting of nDCs
Of the different nDC subsets, the CD141+ mDCs are the
only subset that has not been explored in a clinical trial
yet. The isolation of these cells is even more challenging
because of their extreme scarcity in peripheral blood
(0.2–0.3% of total mononuclear leukocytes). With re-
cently developed isolation kits, the cells can be isolated
with a purity of 70–85% after positive selection for
CD141 and 3-6 × 106 cells can be obtained from one
leukapheresis. This subset is truly specialized in
cross-presentation and a similar subset in mice,
Batf3-dependent CD8α+ lymphoid or CD103+ DCs, were
shown to be crucial for the induction of antitumor
T-cell responses and tumor control [35, 37, 59]. These
mouse equivalents of human CD141+ mDCs are also es-
sential for recruitment of T-cells within the tumor and
effective checkpoint antibody therapy [91, 92]. Moreover,
there is a strong link of mDC infiltration in the tumor
with increased survival in several cancers in The Cancer
Genome Atlas [36, 37, 93]. Therefore, vaccination with
this subset of CD141+ mDCs is postulated to result in
superior antitumor immune responses in cancer patients
and is being optimized for clinical application.
A different path to improve DC vaccines might the
use of neoantigens. Neoantigens are generated by som-
atic mutations in the tumor. Exploiting neoantigens re-
quires sequencing of the tumor of the patients and
prediction of their MHC molecule binding capacity. Al-
though labor-intensive and time-consuming, it is feasible
and might be the future for antigen loading of DCs [94–
96]. Alternatively, intratumoral injection of DCs is
currently under evaluation for its potential to capture
unknown neoantigens in vivo.
Another recent approach to exploit DCs for cancer
immunotherapy is to target DCs subsets in vivo, by anti-
bodies with activating agents and antigens [97]. Antigen
bound to antibodies directed against surface receptors of
DCs that are implicated in endocytosis, can lead to up-
take of the antigen, loading on MHC, and subsequent
induction of immune responses [98]. However, if these
antibody-antigen conjugates are not accompanied by ad-
juvant to stimulate the immune system, tolerance rather
than immunity might occur. The adjuvant can be given
systemically, locally or specifically targeted to nDCs by
antibody-coated (nano)particles loaded with both anti-
gen and adjuvant [99]. The advantage of the latter ap-
proach is that adjuvants only activate those DCs that are
targeted by the antibodies, thereby preventing systemic
activation and toxicity, and conversely, that DCs loaded
with antigens are also stimulated and matured with adju-
vant, so no immature DCs are loaded with tumor anti-
gens [100]. The main advantage of in vivo targeting
strategies is the development of an off-the-shelf product.
However, further research is needed before clinical trials
can be started.
Conclusion
Based on all the in vitro data, nDCs may be a potent
and more practical alternative to moDCs. Currently,
with immunomagnetic isolation the scarce nDCs can be
obtained for DC vaccination. The advantage of nDCs lies
in the rapid and highly standardized, automated produc-
tion of the vaccines, which can improve the quality of
the DC vaccines and enables multicenter trials. Further-
more, as nDCs are not artificially differentiated and only
undergo a short ex vivo culture period, it is hypothesized
that they retain their functional capabilities and avert ex-
haustion. The results from the few completed trials with
nDCs show promising results with very limited toxicity.
Subsequent trials as well as data from ongoing trials will
have to substantiate the role of nDCs in DC-based im-
munotherapy as data is currently too limited to draw
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firm conclusions regarding nDCs and their comparison
to moDCs. It will be interesting to investigate what DC
vaccines can offer and whether their therapeutic effects
can enhance those of checkpoint inhibitors when used
in combination.
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Table 2 Baseline characteristics and outcome measures after natural dendritic cell vaccination
pDC-MEL1 mDC-MEL1 mDC-PROS2
Cancer type Melanoma Melanoma Prostate
Patients Male/female 10/5 10/4 12/0
Age, years Median (range) 52 (35–69) 50 (31–73) 69.5 (52–78)
Disease stage M1a 1 4a 2
M1b 8 2 5
M1c 6 9 3
Unknown 0 0 2
Line of systemic treatment 1st line 14 14 0
2nd line or later 1 0 12b
Number of vaccines received 2 or 3 12 9 12
6 2 2 –
9 1 3 –
Vaccine-specific toxicity Grade 1 6 4 n.a.
Grade 2 0 1 n.a.
Immunological responses Control antigenc (blood) T-cell: 10/14
Ab: 12/15
T-cell. 11/13
Ab: 4/13
T-cell: n.t.
Ab: 4/12
Control antigen (DTH) n.t. n.t. 4/12d
Tumor antigen (blood) 7/15e 4/12 0/12
Tumor antigen (DTH) 2/15 4/13 0/12d
Progression-free survival Median (range; months) 4.0 (< 4–20) 2.8 (< 4–67+) n.a.
Overall survival Median (range; months) 22.3 (< 4–64) 13.3 (< 4–67+) 18 (6–40+)
aIncluding 1 irresectable stage III melanoma patient
bAll patients received 2–4 lines of hormonal treatment. Four patients received prior chemotherapy
cT-cell proliferation upon stimulation with the control antigen (T-cell) and control antigen-specific antibodies (Ab) are shown
dSkin reaction tested only
eNo tumor-specific T-cells were detected prior to restimulation
Abbreviations: n.a., not available; n.t., not tested
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